Literature DB >> 31755208

Increased cancer rates in patients with chronic hepatitis C.

Anders H Nyberg1, Ekaterina Sadikova2, Craig Cheetham3, Kevin M Chiang4, Jiaxiao X Shi5, Susan Caparosa5, Zobair M Younossi6, Lisa M Nyberg1.   

Abstract

AIMS: As previous reports show an association of chronic hepatitis C (HCV) with hepatocellular carcinoma (HCC) and non-liver cancers, we examine the association of HCV with liver cancer and non-liver cancers.
METHODS: Retrospective cross-sectional study at Kaiser Permanente Southern California (KPSC) evaluating HCV and non-HCV patients from 1 January 2008 to 12 December 2012. Cancer diagnoses were obtained from the KPSC-SEER-affiliated registry. Logistic regression analyses were used for rate ratios and time-to-event analyses were performed using Cox proportional hazards models, adjusted for age, gender, race, smoking and cirrhosis. Cancer rate ratios were stratified by tobacco, alcohol abuse, diabetes and body mass index (BMI).
RESULTS: The initial population and final population of multivariable analysis were N = 5 332 903 and N = 2 080 335 respectively. Cancer burden (all sites) was significantly higher in HCV than in non-HCV patients and HCV patients had a high rate of liver cancer. When liver cancer was excluded, cancer rates remained significantly increased in HCV. Unadjusted cancer rates were significantly higher in HCV compared to non-HCV for oesophageal, stomach, colorectal, pancreas, myeloma, non-Hodgkin's lymphoma, head/neck, lung, renal and prostate cancer. After stratification for alcohol abuse, tobacco, diabetes and BMI, increased cancer rates remained significant for all cancer sites, liver cancer and non-Hodgkin's lymphoma. Multivariable analyses demonstrated a strong correlation between cirrhosis and cancer. Tobacco use and diabetes were also associated with cancer. In the absence of cirrhosis, HCV, tobacco use and diabetes significantly increased the cancer risk. Mediation analyses showed that cirrhosis was responsible for a large proportion on the effect of HCV on cancer risk.
CONCLUSION: This study supports the concept of HCV as a systemic illness and treating HCV regardless of disease severity and prior to progression to cirrhosis.
© 2019 Southern California Permanente Medical Group by 2019 John Wiley & Sons A/S.Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HCV; cancer; cirrhosis; comorbidities; hepatitis C; hepatocellular carcinoma

Mesh:

Year:  2019        PMID: 31755208     DOI: 10.1111/liv.14305

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

Review 1.  Chronic Viral Hepatitis Is Associated with Colorectal Neoplasia: A Systematic Review and Meta-Analysis.

Authors:  Seung Wook Hong; Won-Mook Choi; Ha Won Hwang; Dae Sung Kim; Jiyoung Yoon; Jin Wook Lee; Ju Hyun Shim; Dong-Hoon Yang; Seung-Jae Myung; Suk-Kyun Yang; Jeong-Sik Byeon
Journal:  Dig Dis Sci       Date:  2021-01-12       Impact factor: 3.199

Review 2.  Association between viral infection other than human papillomavirus and risk of esophageal carcinoma: a comprehensive meta-analysis of epidemiological studies.

Authors:  Hui Geng; Yaqi Xing; Jingbing Zhang; Kexin Cao; Meijie Ye; Geng Wang; Caixia Liu
Journal:  Arch Virol       Date:  2021-10-12       Impact factor: 2.574

3.  Differential role of chronic liver diseases on the incidence of cancer: a longitudinal analysis among 248,224 outpatients in Germany.

Authors:  Sven H Loosen; David Schöler; Mark Luedde; Johannes Eschrich; Tom Luedde; Karel Kostev; Christoph Roderburg
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-22       Impact factor: 4.322

4.  Patterns of Comorbidity in Hepatocellular Carcinoma: A Network Perspective.

Authors:  Xiao-Min Mu; Wei Wang; Yu-Ying Jiang; Jia Feng
Journal:  Int J Environ Res Public Health       Date:  2020-04-29       Impact factor: 3.390

5.  Chronic Hepatitis Virus Infection Are Associated With High Risk of Gastric Cancer: A Systematic Review and Cumulative Analysis.

Authors:  Yusha Yang; Zufu Jiang; Weizhou Wu; Libin Ruan; Chengyang Yu; Yuning Xi; Liling Wang; Kunpeng Wang; Jinggang Mo; Shankun Zhao
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.